Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Lisa B LeypoldtDiana TichyBritta BesemerMathias HänelMarc-Steffen RaabChristoph MannMarkus MunderHans Christian ReinhardtAxel NogaiMartin GörnerYon-Dschun KoMaike de WitHans J SalwenderChristof ScheidUllrich GraevenRudolf PecenyPeter StaibAnnette DieingHermann EinseleAnna JauchMichael HundemerManola ZagoEma PožekAxel BennerCarsten BokemeyerHartmut GoldschmidtKatja C WeiselPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Isa-KRd effectively induces high rates of sustainable MRD negativity in the difficult-to-treat HRNDMM population, regardless of transplant status, translating into a median PFS that was not yet reached after 44/33 months.